Dr. rer. nat.
Christine Cirl
LL.M.
Dipl.-Biol.
Patent Attorney
European Patent Attorney
European Trade Mark and Design Attorney
Representative before the UPC
Dr. rer. nat.
Christine Cirl
LL.M.
Dipl.-Biol.
Patent Attorney
European Patent Attorney
European Trade Mark and Design Attorney
Representative before the UPC
Christine Cirl advises and supports national and international clients in all areas of biotechnology, including pharmaceuticals, plant biotechnology, diagnostics and food technology. She is particularly experienced in preparing FTO reports and legal opinions, as well as IP landscape and portfolio analyses as an integral part of strategic portfolio consulting. Commencing with the drafting of patent applications and designing of application strategies, her work focuses on preparing and conducting complex patent opposition proceedings and actions for revocation. Christine Cirl’s key areas of technological expertise are immunology (antibodies, vaccines, cancer immunotherapy) and protein technology, including genome editing techniques (including CRISPR/Cas).
According to Handelsblatt/Best Lawyers, Christine Cirl ranks as one of Germany’s best lawyers in 2024 in the field of Patent Law.
She speaks German, English, French and Japanese (basic skills).
Contact
Dr. rer. nat.
Christine Cirl
LL.M.
Dipl.-Biol.
Patent Attorney
European Patent Attorney
European Trade Mark and Design Attorney
Representative before the UPC
Partner
Tel +49 89 549075-0
ccirl@eisenfuhr.com
Eisenführ Speiser
Gollierstraße 4
80339 Munich
Industries
Technical focus
- Biotechnology (plant biotechnology; breeding)
- Genome editing (CRISPR/Cas etc.)
- Immunology (antibodies, vaccines, immuno-oncology)
- Biochemistry
- Microbiology
- Food chemistry
CV
Studied Biology with focus on Technical Biology at Technical University (TU) Munich, Max Planck Institute for Biochemistry, Munich, and at GSF (Helmholtz Center Munich, department: Gene vectors), specializing on Rational Protein Engineering; post-graduate studies and PhD (Dr. rer. nat.) and PostDoc at Institute for Medical Microbiology, Immunology and Hygiene, TU Munich; professional experience in the (re)insurance business (MunichRe and Allianz; areas: risk management, sustainability, due diligence).
Legal training at an international law firm with accompanying legal studies at the Distance-Learning University of Hagen, at the German Patent and Trademark Office and the Federal Patent Court in Munich. Distance-Learning University of Hagen: Master’s degree in European Intellectual Property, LL.M. 2019. Patent Attorney (Germany) since 2014, European Patent Attorney since 2015. At Eisenführ Speiser since 2015.
Memberships
- Patent Attorneys Association (PAK)
- Institute of Professional Representatives before the European Patent Office (epi)
- Society for Biochemistry and Molecular Biology (GBM)
Publications & Presentations
Recent Case Law in German Patent Law 2023
published by Eisenführ Speiser
Locked-out Before the UPC’s doors: Temporal Scope of Art. 83(4) UPCA and R. 5.8 RoP
Case note to UPC Helsinki Local Division, Decision of 20 October 2023, UPC_CFI_214/2023, EPLP - European Patent Litigation in Practice 01/2021
Recent Case Law in German Patent Law 2022
published by Eisenführ Speiser
"Inescapable Opt-Out-Trap? Scope of the blocking effect of former national proceedings with regard to the withdrawal of an Opt-out of the exclusive competence of the Unified Patent Court (UPC)"
Article in Mitteilungen der deutschen Patentanwälte, Edition 01/2023, 4-7
Recent Case Law in German Patent Law 2021
published by Eisenführ Speiser
Recent Case Law in German Patent Law 2020
published by Eisenführ Speiser
Recent Case Law in German Patent Law 2019
published by Eisenführ Speiser
Recent Case Law in German Patent Law 2018
published by Eisenführ Speiser
Uropathogenic Escherichia coli strain CFT073 disrupts NLRP3 inflammasome activation
J. Clin. Invest, 126(7): 2425-36
Weitere Autoren: Waldhuber A., Puthia M., Wieser A, Dürr S., Neumann-Pfeifer S., Albrecht S.
Beitrag zum Tagungsband sowie Vortrag zum Thema "Analyse von Patentportfolios: Generierung aussagekräftiger Ergebnisse als Entscheidungshilfe für die strategische Planung"
im Rahmen der PATINFO 2016 "Big Data - Chancen und Herausforderungen", 8. bis 10. Juni 2016, Ilmenau
A Comparative Analysis of the Mechanism of Toll-Like Receptor-Disruption by TIR-Containing Protein C from Uropathogenic Escherichia coli
Pathogens, 5(1): pii: E25
Weitere Autoren/Further authors: Waldhuber A., Snyder G.A.
Crystal structures of the Toll/Interleukin-1 receptor (TIR) domains from the Brucella protein TcpB and host adaptor TIRAP reveal mechanisms of molecular mimicry
J. Biol. Chem., 2014, Jan. 10, 289(2), 669-79
Weitere Autoren: Snyder, G.A., Deredge, D., Waldhuber, A., Fresquez, T., Wilkins, D.Z., Smith, P.T., Duerr, S., Jiang, J., Jennings, W., Luchetti, T., Snyder, N., Sundberg, E.J., Wintrode, P., Miethke, T., Xiao, T.S
Molecular mechanisms for the subversion of MyD88 signaling by TcpC from virulent uropathogenic E. coli
PNAS, 2013, 110 (17), 6985-6990. Weitere Autoren: Snyder, G. A., Jiang, J., Chen, K., Waldhuber, A., Smith, P., Römmler, F., Snyder, N., Fresquez, T., Dürr, S., Tjandra, N., Miethke, T., Xiao, T.S.
Toll-like receptors 2 and 4 regulate the frequency of IFNγ-producing CD4+ T-cells during pulmonary infection with Chlamydia pneumoniae
PLoS One, 2011, e26101
Weitere Autoren: Wantia, N., Rodriguez, N., Ertl, T., Dürr, S., Layland, L.E., Wagner, H., Miethke, T.
Inhibition of TIR domain signaling by TcpC: MyD88-dependent and independent effects on Escherichia coli virulence
PLoS Pathogens, 26 (9), e1001120
Weitere Autoren: Yadav, M., Zhang, J., Fischer, H., Huang, W., Lutay, N., Lum, J., Miethke, T., Svanborg, C.
Structural studies of Toll like receptor signalling adaptors
Journal of Immunology, 2010, 134, 136.45
Weitere Autoren/Further authors: Snyder, G., Jiang, J., Chen, K., Fresquez, T., Smith, P., Snyder, N., Luchetti, T., Miethke, M., Tjandra, N., Xiao, T.
Microbial Toll/Interleukin-1 receptor proteins: a new class of virulence factors
300 (6), 396-401
Weiterer Autor: Miethke, T.
Chlamydophila pneumoniae downregulates MHC-class II expression by two cell type-specific mechanisms
Mol. Microbiol., 76 (3), 648-661
Weitere Autoren: Peschel, G., Kernschmidt, L., Cirl, C., Wantia, N., Ertl, T., Dürr, S., Wagner, H., Miethke, T., Rodríguez, N.
Induction of iNOS by Chlamydophila pneumoniae requires MyD88-dependent activation of JNK
J. Leukoc. Biol. 84 (6), 1585-1593
Weitere Autoren: Rodriguez, N., Lang, R., Wantia, N., Ertl, T., Dürr, S., Wagner, H., Miethke, T.
Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins
Nature Medicine, 14 (4), 399-406
Weitere Autoren: Wieser, A., Yadav, M., Duerr, S., Schubert, S., Fischer, H., Stappert, D., Wantia, N., Rodriguez, N., Wagner, H., Svanborg, C., Miethke, T.